Molecular Quality Controls Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The molecular quality controls market studied was anticipated to grow with a CAGR of nearly 10.5% during the forecast period. The major factors attributing to the growth of the market are a rise in the global prevalence of infectious diseases, HIV, cancers which necessitate novel diagnostic methods for efficient treatment and quality controls to monitor their performance. For instance, according to the Joint United Nations Programme on HIV and AIDS (UNAIDS) report published in 2019, 24.5 million people with HIV were accessing antiretroviral therapy globally. Additionally, increased participation of the government to control the outbreaks of infectious diseases and a rise in the demand for quality assessment support along with immediate diagnosis systems are expected to contribute to the growth of the global market during the forecast period

Key Market Trends

Independent Controls are Expected to Hold the Largest Market Share in the Molecular Quality Controls Market

Independent controls are anticipated to hold the largest market share in the molecular quality controls market due to their highly precise, unbiased, and independent assessment of a testing system or method performance test results in a short time with the highest sensitivity rate as they are manufactured independently of the instrument, reagents, and calibrators. Furthermore, a steep rise in the adoption of these products among the third-party independent quality controls owing to their benefits such as a wide range of applications along with reduced operational costs is also expected to drive the use of independent controls fueling the market.

Based on the application, the oncology segment accounts for the highest market revenue due to the rising global prevalence of cancer, increasing research on cancer biomarkers, advanced diagnosis infrastructure and growing focus on personalized medicine. On the other hand, genetic testing is expected to witness the highest CAGR during the forecast period due to the rise in their application in the treatment and genetic diagnosis of various genetically inherited diseases and the determination of bloodlines driving the segment which is likely to propel the global market in the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall molecular quality control market, throughout the forecast period. The high adoption rate of advanced infrastructure, increased number of diagnostic centers and accredited clinical laboratories are factors estimated to fuel the market in the region. In North America, the United States holds the largest market share due to increased patient pool. For instance, as per U.S. Department of Health & Human Services report published in 2020, about 37,832 people in the U.S. were diagnosed with HIV in 2018 and 38,000 new HIV infections still occur in the United States and 6 dependent areas each year which results in rapid spread of various infectious diseases such as meningitis, urinary tract infections fueling the market contributing its outstanding share of the global market revenue during the forecast period

Competitive Landscape

The molecular quality control market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by adopting various strategies such as acquisitions and mergers, while others are developing new methods for the treatment and introducing new products to maintain their market share. For instance, in April 2019, Bruker expanded its portfolio for microbial identification, infection control, and molecular diagnostics of infectious diseases by introducing new assays, software and library extensions for its MALDI Biotyper, IR Biotyper, and Fluorocycler XT product lines which are expected to have a positive impact on the market. Some of the companies which are currently dominating the market are Bio-Rad Laboratories Inc F. Hoffmann-La Roche AG, SeraCare Life Sciences Inc, bioMerieux Inc, and ZeptoMetrix Corporation.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support